WO2020237724A1 - 皱盖假芝多糖f212的制备方法和用于预防和/或治疗乳腺癌的应用 - Google Patents
皱盖假芝多糖f212的制备方法和用于预防和/或治疗乳腺癌的应用 Download PDFInfo
- Publication number
- WO2020237724A1 WO2020237724A1 PCT/CN2019/090763 CN2019090763W WO2020237724A1 WO 2020237724 A1 WO2020237724 A1 WO 2020237724A1 CN 2019090763 W CN2019090763 W CN 2019090763W WO 2020237724 A1 WO2020237724 A1 WO 2020237724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- polysaccharide
- cells
- fructus
- preparation
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 68
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 68
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 68
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 52
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title abstract description 4
- 241000143446 Amauroderma rude Species 0.000 title abstract 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930182830 galactose Natural products 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 241000698291 Rugosa Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 240000008397 Ganoderma lucidum Species 0.000 claims description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 23
- 239000002253 acid Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000178993 Brassica juncea Species 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- a medicine or health care product for preventing and/or treating breast cancer which comprises an effective amount of Polysaccharide F212 and a pharmaceutically acceptable carrier.
- Polysaccharides are important active ingredients of edible and medicinal fungi.
- the inventors separated and purified the crude polysaccharide from Fructus rugosa, obtained polysaccharide F212 with significant anti-tumor activity, and analyzed its composition and structural characteristics.
- the breast cancer is breast cancer induced by breast cancer cells 4T1 cells or MDA-MB-231.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
- 一种皱盖假芝多糖F212的制备方法,其特征在于,包括:(1)将皱盖假芝子实体经干燥、粉碎、水浸提,优选用热水进行浸提,得到皱盖假芝水提液,向水提液中加入酒精,优选为质量百分浓度为95%-100%的酒精,进一步优选为质量百分浓度为95%的酒精,调节至酒精质量百分浓度为80%,常温静置,优选静置过夜,后离心,将沉淀分离收集沉淀物,得到皱盖假芝粗多糖F0;(2)对F0采用DEAE sepharose fast flow进行纯化,采用氯化钠溶液作为洗脱液进行梯度洗脱,流速优选为20-40ml/min,氯化钠溶液的浓度优选为0.1、0.5、1、2Mol/l,收集得到4个组分;(3)采用乳腺癌细胞对4个组分进行活性筛选,得到活性最好的组分F1;(4)采用Sephaacyl S-200 chromatography对组分F1进行纯化,用水优选纯水进行洗脱,流速2-5ml/min,根据多糖含量收集得到3个组分;(5)采用乳腺癌细胞对3个组分进行活性筛选,得到活性最好的组分F212;所述皱盖假芝多糖F212,按照质量百分比的单糖组成为:核糖4.3%,鼠李糖0.7%,阿拉伯糖5.3%,木糖4.5%,甘露糖30.5%,葡萄糖37.3%,半乳糖17.4%。
- 根据权利要求1所述的制备方法,其特征在于,采用乳腺癌细胞进行活性筛选的过程包括:(1)制备乳腺癌细胞液;(2)向乳腺癌细胞液中加入样品组分;(3)培养后测定乳腺癌细胞的增殖情况。
- 根据权利要求2所述的制备方法,其特征在于,所述乳腺癌细胞为乳腺癌细胞4T1细胞或MDA-MB-231细胞。
- 一种权利要求1至3所述的制备方法制备得到的皱盖假芝多糖F212。
- 一种皱盖假芝多糖F212的应用,其特征在于,用于制备预防和/或治疗乳腺癌的药物或保健品。
- 根据权利要求5所述的应用,其特征在于,所述乳腺癌为乳腺癌细胞4T1细胞或MDA-MB-231引发的乳腺癌。
- 一种预防和/或治疗乳腺癌的药物或保健品,其特征在于,包括有效量的皱盖假芝多糖F212和药学上可接受的载体。
- 根据权利要求7所述的药物或保健品,其特征在于,所述乳腺癌为乳腺癌细胞4T1细胞或MDA-MB-231引发的乳腺癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910437189.3 | 2019-05-24 | ||
CN201910437189.3A CN110078842B (zh) | 2019-05-24 | 2019-05-24 | 皱盖假芝多糖f212的制备方法和用于预防和/或治疗乳腺癌的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020237724A1 true WO2020237724A1 (zh) | 2020-12-03 |
Family
ID=67421654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/090763 WO2020237724A1 (zh) | 2019-05-24 | 2019-06-11 | 皱盖假芝多糖f212的制备方法和用于预防和/或治疗乳腺癌的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110078842B (zh) |
WO (1) | WO2020237724A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725521A (zh) * | 2015-03-31 | 2015-06-24 | 广东省微生物研究所 | 一种皱盖假芝单峰多糖f212及其制备方法和应用 |
CN108753869A (zh) * | 2018-06-26 | 2018-11-06 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种皱盖假芝胞外多糖的制备方法及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258563B (zh) * | 2010-05-28 | 2013-06-26 | 浦元清 | 一种抗癌药物组合物和一种中药组合物 |
-
2019
- 2019-05-24 CN CN201910437189.3A patent/CN110078842B/zh active Active
- 2019-06-11 WO PCT/CN2019/090763 patent/WO2020237724A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725521A (zh) * | 2015-03-31 | 2015-06-24 | 广东省微生物研究所 | 一种皱盖假芝单峰多糖f212及其制备方法和应用 |
CN108753869A (zh) * | 2018-06-26 | 2018-11-06 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种皱盖假芝胞外多糖的制备方法及应用 |
Non-Patent Citations (2)
Title |
---|
JIAO C. W. ET AL.: "Anticancer Activity of Amauroderma rude", PLOS ONE, vol. 8, no. 6, 30 June 2013 (2013-06-30), XP055757010, ISSN: 1932-6203, DOI: 20200221131942A * |
ZHANG, YIFAN ET AL.: "Research Progress on Efficacy of Amauroderma Rugosum", EDIBLE FUNGI, no. 2,, 31 December 2018 (2018-12-31), ISSN: 1000-8357, DOI: 20200221131429A * |
Also Published As
Publication number | Publication date |
---|---|
CN110078842A (zh) | 2019-08-02 |
CN110078842B (zh) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108530552B (zh) | 昆布多糖的制备及在制备抗肿瘤药物中的应用 | |
CN109400741B (zh) | 一种灵芝孢子多糖的分离纯化方法 | |
CN110128562A (zh) | 一种抗肿瘤补骨脂多糖及其提取分离方法和在制备抗肿瘤药物方面的应用 | |
CN104042623A (zh) | 一种黑根霉胞外多糖在制备治疗或预防消化道肿瘤药物中的应用 | |
CN103751225B (zh) | 蛹虫草抗肿瘤活性组分的提取方法及其应用 | |
WO2020237724A1 (zh) | 皱盖假芝多糖f212的制备方法和用于预防和/或治疗乳腺癌的应用 | |
CN108424469B (zh) | 一种芡实种仁多糖及其分离提取方法和用途 | |
CN110156904A (zh) | 紫甘薯多糖在制备抗肺癌药物中的应用 | |
CN103169752B (zh) | 一种木鳖子提取物及其制备方法和用途 | |
CN113717296B (zh) | 一种杜仲酸性多糖、提取方法及其在制备抗结肠癌药物中的应用 | |
CN112237588B (zh) | 一种平菇多糖硒苷-ⅲ抗癌活性成分在制备抗前列腺癌的药物中的应用 | |
CN110522776B (zh) | 一种黄槿中抗肿瘤有效部位的制备方法及应用 | |
CN103374078A (zh) | 紫芝液体深层发酵菌丝体均一多糖及其制备方法以及应用 | |
CN103169753B (zh) | 木鳖子活性提取物在制备抗呼吸系统肿瘤药物中的应用 | |
CN116120475B (zh) | 一种云莓均一多糖rcp-90-1及其分离纯化方法和作为抗肿瘤药物的应用 | |
CN105177081B (zh) | 黄绿蜜环菌发酵液有效部位的制备方法及应用 | |
WO2014173057A1 (zh) | 一种槐耳多糖蛋白及其制备方法和用途 | |
CN113880960B (zh) | 一种抗缺氧活性铁皮石斛多糖及其蒸汽爆破制备方法和应用 | |
CN114437244B (zh) | 一种具有抗肺癌a549细胞增殖功能的枸杞多糖提取物 | |
CN116693716B (zh) | 一种金果榄多糖及其制备方法和应用 | |
CN114409824B (zh) | 毛霉胞外多糖及其制备方法和应用 | |
CN112220798B (zh) | 一种平菇多糖硒苷-ⅲ在制备治疗卵巢癌的药物中的应用 | |
CN115141288B (zh) | 知母活性多糖、知母粗多糖及制备方法和应用 | |
CN112274530B (zh) | 一种平菇多糖硒苷-ⅲ抗癌活性成分在用于制备抗乳腺癌的药物中的应用 | |
CN110894244B (zh) | 一种土鳖虫多糖的结构及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19930684 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19930684 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19.01.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19930684 Country of ref document: EP Kind code of ref document: A1 |